Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01491074

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01491074
  • EudraCT 2010-021953-37
Other papers using this trial's data
  • Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction International journal of cardiology, 2018-11-15 DOI, PubMed 29961572

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01491074. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
Condition
Non-ST Elevation Myocardial Infarction
Intervention (Drug)
Tocilizumab 280 mg
Intervention (Drug)
NaCl 0.9% 100 ml
Lead sponsor
Oslo University Hospital (class: other)
Collaborator
St. Olavs Hospital (class: other)
Collaborator
South-Eastern Norway Regional Health Authority (class: other)
Collaborator
University of Oslo (class: other)
Collaborator
Norwegian University of Science and Technology (class: other)

Record details

Record id
cardio:ct-nct01491074
Content hash
5d8891fa5a92fbecef68084db99d96569dda660752f2ba0acf2b1464e31dab6d